Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
17 Marzo 2023 - 12:00PM
Business Wire
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a
biopharmaceutical company focused on novel and targeted oncology
therapies, today announced it will host a conference call to
discuss the fourth quarter and full year 2022 financial results and
provide a corporate update on Wednesday, March 22, 2023, at 8:30
a.m. Eastern/5:30 a.m. Pacific.
Conference Call and Webcast:
Wednesday, March 22, 2023 @ 8:30 a.m.
Eastern/5:30 a.m. Pacific
To access the live call by phone, please go to this link
(registration link) , and you will be provided with dial in
details. To avoid delays, we encourage participants to dial into
the conference call fifteen minutes ahead of the scheduled start
time.
A live webcast of the call will be available online in the
Investor Relations section of the company’s website at
http://investor.sppirx.com/events-and-presentations and will be
archived there shortly after the live event.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company
focused on acquiring, developing, and commercializing novel and
targeted oncology therapies. Spectrum has a strong track record of
successfully executing across the biopharmaceutical business model,
from in-licensing and acquiring differentiated drugs, clinically
developing novel assets, successfully gaining regulatory approvals
and commercializing in a competitive healthcare marketplace. For
additional information on Spectrum please visit www.sppirx.com.
Notice Regarding Forward-looking statements
This press release may contain forward-looking statements
regarding future events and the future performance of Spectrum
Pharmaceuticals that involve risks and uncertainties that could
cause actual results to differ materially. These statements are
based on management's current beliefs and expectations. These
statements include, but are not limited to, statements that relate
to Spectrum’s business and its future, including Spectrum's ability
to successfully execute across the biopharmaceutical business
model, including successfully gaining regulatory approvals and
commercializing in a competitive healthcare marketplace, and any
statements that relate to the intent, belief, plans or expectations
of Spectrum or its management, or that are not a statement of
historical fact. Risks that could cause actual results to differ
include the possibility that Spectrum’s existing and new drug
candidates may not prove safe or effective, the possibility that
our existing and new applications to the FDA and other regulatory
agencies may not receive approval in a timely manner or at all, the
possibility that our existing and new drug candidates, if approved,
may not be more effective, safer or more cost efficient than
competing drugs, the possibility that our efforts to acquire or
in-license and develop additional drug candidates may fail, the
possibility that our commercialization efforts may not be
successful, our dependence on third parties for manufacturing,
distribution and quality control and other risks that are described
in further detail in the company's reports filed with the
Securities and Exchange Commission. The company does not plan to
update any such forward-looking statements and expressly disclaims
any duty to update the information contained in this press release
except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of
Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING
CANCER CARE™ is Spectrum Pharmaceuticals’ logo and trademarks owned
by Spectrum Pharmaceuticals, Inc. Any other trademarks are the
property of their respective owners.
© 2023 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230317005040/en/
Tom Riga Chief Executive Officer 949.788.6700
InvestorRelations@sppirx.com
Lisa Wilson In-Site Communications, Inc. 212.452.2793
lwilson@insitecony.com
Grafico Azioni Spectrum Pharmaceuticals (NASDAQ:SPPI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Spectrum Pharmaceuticals (NASDAQ:SPPI)
Storico
Da Giu 2023 a Giu 2024